[
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Weaker Late Afternoon",
    "summary": "Health care stocks were decreasing late Friday afternoon, with the NYSE Health Care Index down 0.6%",
    "url": "https://finnhub.io/api/news?id=f04e9fe1bb841f0ab1bf4071f17feeac75585ccf407f7572aedb2da8426c3b95",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736542682,
      "headline": "Sector Update: Health Care Stocks Weaker Late Afternoon",
      "id": 132375120,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks were decreasing late Friday afternoon, with the NYSE Health Care Index down 0.6%",
      "url": "https://finnhub.io/api/news?id=f04e9fe1bb841f0ab1bf4071f17feeac75585ccf407f7572aedb2da8426c3b95"
    }
  },
  {
    "ts": null,
    "headline": "AI, vaccine distrust, & the future of healthcare: Novartis CEO",
    "summary": "Can science prevail against this more turbulent backdrop of the Trump administration? Yahoo Finance executive editor Brian Sozzi talks at length with Novartis (NVS) CEO Vas Narasimhan. Narasimhan has led the drug giant since 2018, doing deals that have expanded the company’s pipeline in areas like heart disease and cancer. Still, Narasimhan is feeling pressure to bring the investments to the bottom line to jumpstart a stock price that has lagged in the past year. For full episodes of Opening Bid, listen on your favorite podcast platform or watch on our website.",
    "url": "https://finnhub.io/api/news?id=be29e0e1d1de1f0cf67bbfce15ae9d05e3410ad5a5cd4340317e7ad82a5f045e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736515851,
      "headline": "AI, vaccine distrust, & the future of healthcare: Novartis CEO",
      "id": 132363849,
      "image": "https://s.yimg.com/ny/api/res/1.2/lYz92SON.CgZn.4L3FSanQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzQ-/https://s.yimg.com/os/creatr-uploaded-images/2025-01/c2a28a10-ced6-11ef-8ffe-41aa770da203",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Can science prevail against this more turbulent backdrop of the Trump administration? Yahoo Finance executive editor Brian Sozzi talks at length with Novartis (NVS) CEO Vas Narasimhan. Narasimhan has led the drug giant since 2018, doing deals that have expanded the company’s pipeline in areas like heart disease and cancer. Still, Narasimhan is feeling pressure to bring the investments to the bottom line to jumpstart a stock price that has lagged in the past year. For full episodes of Opening Bid, listen on your favorite podcast platform or watch on our website.",
      "url": "https://finnhub.io/api/news?id=be29e0e1d1de1f0cf67bbfce15ae9d05e3410ad5a5cd4340317e7ad82a5f045e"
    }
  },
  {
    "ts": null,
    "headline": "Trump Says World Is Free-Riding on U.S. Health Spending. He Has a Point.",
    "summary": "The president-elect might bring back efforts to make other countries pay more for drugs, but there are pitfalls.",
    "url": "https://finnhub.io/api/news?id=f64290c4ea41bbb54c1c29a88547004f7df6030de8c2162f41da388823b4bf12",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736505000,
      "headline": "Trump Says World Is Free-Riding on U.S. Health Spending. He Has a Point.",
      "id": 132370440,
      "image": "https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The president-elect might bring back efforts to make other countries pay more for drugs, but there are pitfalls.",
      "url": "https://finnhub.io/api/news?id=f64290c4ea41bbb54c1c29a88547004f7df6030de8c2162f41da388823b4bf12"
    }
  },
  {
    "ts": null,
    "headline": "ClearBridge Appreciation Strategy Q4 2024 Commentary",
    "summary": "The Strategy outperformed its benchmark during a volatile quarter, as strong contributions from our financials and energy holdings overcame detractors in consumer staples.",
    "url": "https://finnhub.io/api/news?id=be71aab0b2d2b2410706072f2cd7c2cc78142ae8486f8cd73424913fb6a82738",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736487300,
      "headline": "ClearBridge Appreciation Strategy Q4 2024 Commentary",
      "id": 132360483,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1227017253/image_1227017253.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The Strategy outperformed its benchmark during a volatile quarter, as strong contributions from our financials and energy holdings overcame detractors in consumer staples.",
      "url": "https://finnhub.io/api/news?id=be71aab0b2d2b2410706072f2cd7c2cc78142ae8486f8cd73424913fb6a82738"
    }
  },
  {
    "ts": null,
    "headline": "Alzheimer’s Drugs Eyed by Investors Seeking Obesity-Like Gains",
    "summary": "(Bloomberg) -- Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025.Most Read from BloombergWhat Robotaxis Brought San FranciscoNYC Condo Owners May Bear Costs of Landmark Green Building LawNYC’s Subway Violence Deters Drive to Bring Workers Back to OfficeAmbitious High-Speed Rail Plans Advance in the Baltic RegionDutch Central Bank Restores Amsterdam’s ‘Ugliest Building’Companies including Biogen I",
    "url": "https://finnhub.io/api/news?id=ea5f36bfd3b0ac504e35d4fa86745f94ba1329858e30a5dc962073caa485c682",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736485200,
      "headline": "Alzheimer’s Drugs Eyed by Investors Seeking Obesity-Like Gains",
      "id": 132357051,
      "image": "https://media.zenfs.com/en/bloomberg_markets_842/29e857c7f809eb552ddff0361e37d60e",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025.Most Read from BloombergWhat Robotaxis Brought San FranciscoNYC Condo Owners May Bear Costs of Landmark Green Building LawNYC’s Subway Violence Deters Drive to Bring Workers Back to OfficeAmbitious High-Speed Rail Plans Advance in the Baltic RegionDutch Central Bank Restores Amsterdam’s ‘Ugliest Building’Companies including Biogen I",
      "url": "https://finnhub.io/api/news?id=ea5f36bfd3b0ac504e35d4fa86745f94ba1329858e30a5dc962073caa485c682"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Vs Novo Nordisk (NVO): Which is the Best Weight Loss Stock for 2025?",
    "summary": "Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly (LLY) and Novo Nordisk (NVO) stock.",
    "url": "https://finnhub.io/api/news?id=733a43ae82be7f67f5fe17b2d4564cf4e0742ed4a17db29d86c70bf4f0e9ec10",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736469240,
      "headline": "Eli Lilly (LLY) Vs Novo Nordisk (NVO): Which is the Best Weight Loss Stock for 2025?",
      "id": 132357052,
      "image": "https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly (LLY) and Novo Nordisk (NVO) stock.",
      "url": "https://finnhub.io/api/news?id=733a43ae82be7f67f5fe17b2d4564cf4e0742ed4a17db29d86c70bf4f0e9ec10"
    }
  }
]